Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer-specific mortality and longer time to distant metastasis compared with EBRT with androgen deprivation therapy or with RP.

No abstract

Very-low-risk prostate cancer patients have a significantly lower incidence of Gleason score upgrading than those with low-risk disease. After TTMB, 83.3% of patients with very-low-risk and 32.2% of patients with low-risk disease appear to be outstanding candidates for AS.

No abstract